Pharmaceutical Technology Licensing: An Analysis in the Field of Cardiovascular Disease

Ni, Jingyun; Wan, Jian-Bo; Kong, Xiangjun; Cai, Yong; Yang, Feng‐Qing; Wang, Ying; Y, Hu

doi:10.1007/s12247-015-9234-5

Cited by 3 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3,4 Actors besides pharmaceutical companies, such as universities, research institutions, and newly founded biotechnology firms, now play pivotal roles in the drug R&D process, especially in therapeutic strategies largely derived from biotechnological innovations. Large pharmaceutical companies have rebuilt borders to facilitate the R&D processes by strategically harnessing their external sources of innovation, including ideas, technologies, and R&D projects 5,6 that could not be generated internally, and have particularly intensified relationships with biotechnology. Biotechnology firms, which denote profit-seeking firms focusing on researching, developing, and commercializing biotechnologies, need certain resources to bring biotech-derived products to market, and are therefore involved in intricate relationships with pharmaceutical companies, universities, and research institutions.…”

Section: Introductionmentioning

confidence: 99%

Evolving patterns in a collaboration network of global R&D on monoclonal antibodies

Kong

Wan

et al. 2017

mAbs

Self Cite

View full text Add to dashboard Cite

We investigated the evolution process of collaborative inter-organizational network of the research and development (R&D) on monoclonal antibody (mAb) over the past 30 y. The annual detection of the collaboration network provides dynamics on network structures and relationship changes among different organizations. Our research showed continuous growth of the network's scale and complexity due to the constant entry of new organizations and the forging of new partnering relationships. The evolving topological features reveal a core-periphery structure that became clearer over time and an increasing heterogeneity within the collaborative mAb R&D network. As measured by the number of network participants, dedicated biotechnology firms (DBFs) were the dominant organization form in the field of mAb development, but their average centrality was reduced during the period of 2004-2009, when pharmaceutical companies took over the positions of DBFs. Along with the network evolution, 2 waves of substitution on the leading positions were driven by technological innovations and mergers and acquisitions (M&A). In addition, this study analyzed organizational-level behaviors to help understand the evolution of network structures over the field of mAb development across the different technologically innovative or economic contexts.

show abstract

Section: Introductionmentioning

confidence: 99%

Evolving patterns in a collaboration network of global R&D on monoclonal antibodies

Kong

Wan

et al. 2017

mAbs

Self Cite

View full text Add to dashboard Cite

show abstract

Research and development of anti-Alzheimer’s disease drugs: an update from the perspective of technology flows

Liu

Lin

Mak

et al. 2018

Expert Opinion on Therapeutic Patents

View full text Add to dashboard Cite

Today, over 20 million people suffer from Alzheimer's disease (AD) worldwide. AD has become a critical issue to human health, especially in aging societies, and therefore it is a research hotspot in the global scientific community. The technology flow method differs from traditional reviews generating an informative overview of the research and development (R&D) landscape in a specific technological area. We need such an updated method to get a general overview of the R&D of anti-AD drugs in light of the dramatic developments in this area in recent years. Areas covered: This study collects patent data from the Integrity database. A total of 399 patents with 821 internal citation pairs in the US from 1978 to 2017 were analyzed. Patent citation network analysis was used to visualize the technology relationship. Expert opinion: For better production of anti-AD drugs, governments should emphasize the multi-target drug design, provide policy support for private companies, and encourage multilateral cooperation. The β-amyloid peptide (Aβ) theory leaves much to be desired; neurotransmitter and tau protein hypotheses are worth further examination. The use of old drugs for new indications is promising, as are traditional herbal medicines.

show abstract

Is the IPO of Bio Venture Companies Intended for R&D? Analysis Study on Listed Bio Venture Companies in Korea

Kang

2024

OJBM

View full text Add to dashboard Cite

Pharmaceutical Technology Licensing: An Analysis in the Field of Cardiovascular Disease

Cited by 3 publications

References 39 publications

Evolving patterns in a collaboration network of global R&D on monoclonal antibodies

Evolving patterns in a collaboration network of global R&D on monoclonal antibodies

Research and development of anti-Alzheimer’s disease drugs: an update from the perspective of technology flows

Is the IPO of Bio Venture Companies Intended for R&D? Analysis Study on Listed Bio Venture Companies in Korea

Contact Info

Product

Resources

About